⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3151200 | 1.00 | — | — | |
| SCHEMBL139619 | 1.00 | — | — | |
| Trimethylammonium SCHEMBL11505010 | 0.91 | CHRNB2 (0.47) | — | |
| Methacrylic Acid SCHEMBL5908013 | 0.85 | TSHR (0.42) | — | |
| SCHEMBL28924343 | 0.81 | ALOX15 (0.41) | — | |
| SCHEMBL30357063 | 0.81 | ALOX15 (0.50) | — | |
| SCHEMBL42755 | 0.81 | — | — | |
| SCHEMBL18641519 | 0.80 | — | — | |
| SCHEMBL29112544 | 0.80 | — | — | |
| SCHEMBL28339731 | 0.80 | ALOX15 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110637015-A | Farnesoin X receptor agonists and uses thereof | 梅塔科林公司 | 2019-12-31 | — | — | CN | claimed |
| CN-119504723-A | Thiophene sulfonyl carbamates as AT2R agonists | 武汉人福创新药物研发中心有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-118239948-A | Solid forms and methods of making fused tricyclic compounds, including methods of use thereof | 豪夫迈·罗氏有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-117946107-A | Solid forms and methods of making fused tricyclic compounds, including methods of use thereof | 豪夫迈·罗氏有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117715909-A | Condensed heterocyclic derivative | 杨森科学爱尔兰无限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-117120429-A | KHK inhibitor | 吉利德科学公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-116323599-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116196435-A | Antibody drug conjugates comprising STING agonists | 梅尔莎纳医疗公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-111971287-B | Macrocyclic compounds as TRK kinase inhibitors | 重庆复尚源创医药技术有限公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-116063326-A | Amino-containing macrocyclic compounds as protein kinase modulators | 赛诺哈勃药业（成都）有限公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-110612285-A | Amide derivatives as Nav1.7 and Nav1.8 blockers | 拉夸里亚创药株式会社 | 2019-12-24 | — | — | CN | disclosed |
| CN-108137539-A | SUBSTITUTED BENZIMIDAZOLES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | 尼奥迈德研究所 | 2018-06-08 | — | — | CN | disclosed |
| US-9676782-B2 | Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of metabotropic glutamate receptor 3 | VANDERBILT UNIVERSITY (US) | 2017-06-13 | — | — | US | disclosed |
| US-20150361081-A1 | NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 3 | VANDERBILT UNIVERSITY | 2015-12-17 | — | — | US | disclosed |
| EP-2245146-B1 | NEW CALB MUTEINS AND THEIR USE | BASF SE (DE) | 2015-04-01 | — | — | EP | disclosed |
| US-8206969-B2 | CALB muteins and their use | BASF SE (DE) | 2012-06-26 | — | — | US | disclosed |
| US-8206969-B2 | CALB muteins and their use | BASF SE (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20100273223-A1 | New Calb Muteins and Their Use | BASF SE (DE) | 2010-10-28 | — | — | US | disclosed |
| US-20100273223-A1 | New Calb Muteins and Their Use | BASF SE (DE) | 2010-10-28 | — | — | US | disclosed |
| WO-2009080676-A1 | NEW CALB MUTEINS AND THEIR USE | BASF SE (DE) | 2009-07-02 | — | — | WO | disclosed |